News & Updates
Filter by Specialty:
Maintenance olaparib confers survival benefit for HRD+ ovarian cancer patients
In the final overall survival (OS) analysis of the phase III PAOLA-1*/ENGOT-ov25 trial, the addition of olaparib to bevacizumab provided a survival benefit for women with newly diagnosed advanced ovarian cancer with HRD**-positive (HRD+) tumours.
Maintenance olaparib confers survival benefit for HRD+ ovarian cancer patients
19 Dec 2022
Large lag between breast cancer symptom onset and clinical consultation in LMICs
In low- and middle-income countries (LMICs), there appears to be a long interval between the first onset of breast cancer symptoms and presentation to a healthcare provider, reports a recent study.
Large lag between breast cancer symptom onset and clinical consultation in LMICs
18 Dec 2022
Cervical cancer screening: Thumbs up for HPV self-sampling among women in SG
Human papillomavirus (HPV) self-sampling for cervical cancer screening is highly acceptable among Singaporean women, with the strategy deemed accurate and easy to perform, a study has found.
Cervical cancer screening: Thumbs up for HPV self-sampling among women in SG
16 Dec 2022
Sotorasib improves PFS over docetaxel in KRASG12C-mutated advanced NSCLC
The first-in-class KRASG12C inhibitor sotorasib significantly improved progression-free survival (PFS) in patients with previously treated non-small cell lung cancer (NSCLC) with KRASG12C mutations, according to results of the phase III CodeBreaK 200 trial presented at ESMO 2022.
Sotorasib improves PFS over docetaxel in KRASG12C-mutated advanced NSCLC
15 Dec 2022
Coexisting diabetes ups risk of secondary malignancy, death in cancer patients
In cancer patients, the presence of diabetes appears to aggravate the likelihood of developing a secondary malignancy or death, reports a recent Japan study.
Coexisting diabetes ups risk of secondary malignancy, death in cancer patients
15 Dec 2022
Prophylactic G-CSF averts febrile neutropaenia in docetaxel-treated breast cancer patients
Prophylactic granulocyte-colony stimulating factor (G-CSF) results in a significant decrease both in the rate of febrile neutropaenia (FN) and duration of hospitalization for FN in breast cancer patients treated with docetaxel-based chemotherapy regimens (DBRs), according to a recent study.
Prophylactic G-CSF averts febrile neutropaenia in docetaxel-treated breast cancer patients
14 Dec 2022
Palbociclib–bazedoxifene combo for HR+/HER2− breast cancer succeeds in early trial
Treatment with the combination of palbociclib plus bazedoxifene demonstrates clinical efficacy while having an acceptable safety profile in treatment-experienced patients with hormone receptor–positive/HER2-negative (HR+/HER2−) advanced breast cancer, according to the results of a phase Ib/II study.
Palbociclib–bazedoxifene combo for HR+/HER2− breast cancer succeeds in early trial
14 Dec 2022
Acalabrutinib-based chemo-free triplet shows high rates of MRD-negative CR in 1L MCL study
First-line (1L) acalabrutinib in combination with lenalidomide and rituximab (ALR) has demonstrated high rates of minimal residual disease (MRD)–negative complete remission (CR) in patients with mantle cell lymphoma (MCL), including patients with TP53 mutations, in a single-arm phase II trial reported at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.